Registration Now Open for Tribe Public’s Webinar Featuring GeoVax Lab’s CEO
Join us for an in-depth discussion about Mpox, including insights on its rapid spread and strategies for control, treatment, and prevention.
Event Overview
GeoVax Lab, Inc. (NASDAQ: GOVX), a biotechnology company dedicated to creating immunotherapies and vaccines for cancers and infectious diseases, has announced that David Dodd, the CEO of GeoVax Labs, will be speaking at Tribe Public’s Webinar Presentation and Q&A Event titled "Now Is Not the Time to Monkey(pox) Around." This informative session is scheduled for 8:00 AM PT / 11:00 AM ET on the upcoming Friday.
Webinar Participation
Those interested can register for this free event and submit their questions for the CEO to Tribe Public. Participants can also pose questions via the ZOOM chat feature during the webinar. The event will be hosted by Tribe Public’s Managing Member, who will facilitate all inquiries.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company that focuses on developing groundbreaking vaccines for infectious diseases and therapies for solid tumor cancers. The company's flagship program is GEO-CM04S1, a next-generation COVID-19 vaccine. Recently, this program received a substantial contract to support a large-scale Phase 2b clinical trial aimed at assessing the effectiveness of GEO-CM04S1 compared to an approved COVID-19 vaccine. Currently, GEO-CM04S1 is involved in three Phase 2 clinical trials targeting different patient groups.
Innovative Cancer Therapies
In the field of oncology, GeoVax is exploring an advanced oncolytic solid tumor gene-directed therapy through a multicenter clinical trial for late-stage cancers. The company has a strong intellectual property portfolio that underpins its technologies and products, holding global rights as it advances its mission.
Contact Information
Company Contact: info@geovax.com | 678-384-7220
Investor Relations Contact: austin.murtagh@precisionaq.com | 212-698-8696
Media Contact: sr@roberts-communications.com | 202-779-0929
Frequently Asked Questions
What is the purpose of the upcoming webinar?
The webinar is designed to provide insights into Mpox, focusing on its rapid spread and the various methods for its control, treatment, and prevention.
Who will be presenting at the webinar?
David Dodd, the CEO of GeoVax Labs, will be the featured presenter at the event.
How can I register for the webinar?
Interested individuals can sign up for the free event on the Tribe Public website.
What is GeoVax Labs known for?
GeoVax Labs is well-known for its work in developing immunotherapies and vaccines targeting cancers and infectious diseases, including innovative strategies for COVID-19.
What are the company’s clinical trial focus areas?
GeoVax concentrates on creating vaccines for infectious diseases and therapies for solid tumor cancers, with a particular emphasis on its clinical trials for the COVID-19 vaccine.